Uncovering the Link between the Gut and Autoimmunity in Patients with PTEN Hamartoma Tumor Syndrome
03/03/2021

A pilot study led by Dr. Eng suggests that the gut microbiome may contribute to the development of autoimmune diseases and immune dysregulation in patients with PTEN hamartoma tumor syndrome.

Read More

 

GMI Postdoc Receives National Cancer Institute Fellowship Award
03/02/2021

With this award, Dr. Fink will investigate the cause of abnormal DNA methylation in colorectal cancer development.

Read More

 

Microbiome Reveals Clues to Male Infertility
02/24/2021

In collaboration with Dr. Eng, Dr. Lundy and colleagues compared the microbiomes of infertile and fertile men and identified several bacterial and metabolic pathway differences that may help diagnose and treat male infertility.

Read More

 

Researchers Develop Interactive Platform to Identify Druggable Cancer Mutations
02/08/2021

Dr. Cheng and team developed a personalized genomic medicine platform to identify clinically actionable mutations and accelerate the development of cancer precision medicine protocols.

Read More

 

W.M. Keck Foundation Grant to Study Potential Link Between Bacteria and Cancer
02/04/2021

Dr. Ting and collaborators from Fred Hutchinson Cancer Research Center will investigate if bacterial enzymes directly modify the human genome to promote cancer.

Read More

 

Study Shows Machine Learning’s Potential to Predict Cancer Therapy-Related Cardiac Risk
01/06/2021

An interdisciplinary team led by Drs. Cheng and Collier developed machine learning models that predict with promising accuracy the risk of cardiac dysfunction in cancer survivors and may be generalizable to clinical practice.

Read More

 

Cleveland Clinic Researchers Use “Big Data” Approach to Identify Melatonin as Possible COVID-19 Treatment
11/09/2020

Dr. Cheng and colleagues developed a network medicine strategy to predict disease manifestations associated with COVID-19 and find existing drugs with the potential to be effective COVID-19 treatments.

Read More

 

Not All Mutations are Bad: Researchers Identify Differences between Benign and Pathogenic Variants
10/26/2020

Dr. Lal’s team conducted the first big data characterization of missense variants from 1,300 disease-associated genes to identify features associated with pathogenic and benign variants.

Read More

 

GMI Graduate Students Win 2020 Lerner Research Institute Awards for Excellence
10/05/2020

Sara Akhavanfard, MD, PhD, and Abigail Dooley were recognized for their outstanding scientific achievements.

Read More

 

GMI Fellow Wins Crile Research Fellowship Award
10/05/2020

With this award, Takae Brewer, MD, aims to provide further insight into the genomics of breast cancer development, invasion and metastasis in the context of PTEN hamartoma tumor syndrome.

Read More

 

New Grant to Investigate Genomic Alterations Influencing PTEN Hamartoma Tumor Syndrome
09/11/2020

Dr. Eng’s team will sequence the genomes of patients with PTEN hamartoma tumor syndrome to determine if and how changes in non-coding regions of the genome affect clinical outcomes.

Read More

 

NIH Supplement Award for COVID-19 Drug Repurposing
09/02/2020

Dr. Cheng and his team aim to identify repurposable drugs and combination regimens to treat COVID-19 in older adults

Read More

 

New NIH Grant to Study Aging-Related Disorders in People with HIV
08/25/2020

Dr. Kallianpur will investigate if kidney disease and cognitive impairment in people with HIV share an underlying mechanism and potentially highlight non-invasive biomarkers for these disorders.

Read More

 

NIH Awards $3.1M to Identify Novel Parkinson’s Disease Genes in Latinos
08/10/2020

Dr. Mata and collaborators aim to pinpoint therapeutic targets for treatment and improve diagnosis and risk prediction in Latino populations.

Read More

 

Genetic Factors May Influence COVID-19 Susceptibility
07/15/2020

Dr. Cheng's team found a possible association between ACE2 and TMPRSS2 polymorphisms and COVID-19 susceptibility.

Read More

 

WWP1 Inactivation of PTEN Drives Cancer Predisposition
05/28/2020

A study co-led by Drs. Eng and Pandolfi identified why patients without PTEN mutations may still experience the high cancer risk associated with PTEN hamartoma tumor syndrome.

Read More

 

Germline Genomic Profiles of Children, Adolescents and Young Adults with Solid Tumors Inform Management and Treatment
05/05/2020

Researchers led by Dr. Eng conducted the largest-to-date evaluation of germline mutations in children, adolescents and young adults with solid tumors and demonstrated the value of genetics evaluation and genetic testing for this patient population.

Read More

 

Uncovering the Link between DNA Methylation and Alternative Polyadenylation in Cancer
04/30/2020

Dr. Ting discovered a DNA methylation-regulated alternative polyadenylation mechanism that may play an important role in cancer development.

Read More

 

GMI Postdoc Wins 2020 Lower Award
04/21/2020

Dr. Lamis Yehia was named the first place winner in the clinical category.

Read More

 

$3.3M NIH Grant for Alzheimer’s Drug Repurposing
04/08/2020

Dr. Cheng will develop and implement computational tools to identify and test novel repurposable drugs and drug combinations for Alzheimer’s disease.

Read More

 

Galaxy Closes a Data Interoperability Loop
03/16/2020

Read More

 

Network-Based Drug Discovery for the Emerging COVID-19 Epidemic
03/16/2020

By harnessing the powers of systems pharmacology and predictive modeling, Dr. Cheng identified 16 drugs and three drug combinations that may be candidates for repurposing as potential COVID-19 treatments.

Read More

 

Researchers Calculate Incidence Estimates for More than 100 Rare Brain Disorders
03/12/2020

Dr. Lal adjusted and used a statistical model based on mutation rate to predict the annual number of new cases of over 100 rare monogenetic neurodevelopmental disorders caused by de novo variants, offering previously unavailable estimates for disease burden.

Read More

 

Harnessing AI for Drug Repurposing
02/12/2020

A systems biology and network medicine expert, Dr. Cheng developed a deep learning methodology to more accurately predict drug-target interactions, which will help accelerate drug repurposing efforts.

Read More